Wednesday, February 10, 2010, 1:01PM AEST - The Australian Stockmarket closes in 3 hours and 4 minutes.
To create a watchlist or portfolio of shares, Register

Rosetta Genomics, Ltd. (ROSG)

7:59AM AEST: 1.61 USD  Down 0.04 (2.42%)  
 MORE ON ROSG 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Rosetta Genomics Ltd. (NGM:ROSG) Delayed quote dataEdit
Last Trade:1.61 USD
Trade Time: 7:59AM AEST
Change:Down 0.04 (2.42%)
Prev Close:1.65
Open:1.62
Bid:1.38 x 3500
Ask:N/A
1y Target Est:N/A
Day's Range:1.59 - 1.67
52wk Range:1.59 - 3.80
Volume:46,247
Avg Vol (3m):90,725.4
Market Cap:22.82M
P/E (ttm):N/A
EPS (ttm):-0.87
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add ROSG to Portfolio   Download Data

 HEADLINES 
Rosetta Genomics Announces Issuance of Three U.S. Patents
Business Wire (Wed, Feb 3)
Rosetta Genomics Fortifies Patent Position with U.S. Allowance of Claims Covering Human microRNAs miR-21 and hcmv-miR-UL112
Business Wire (Sat, Jan 30)
Rosetta Genomics Ltd. Closes $5.1 Million Financing; Will Support Ongoing Development of microRNA-based Diagnostic Pipeline
Business Wire (Wed, Jan 20)
Medifast, Rosetta Genomics: Biggest Price Decliners (MED, ROSG)
at The Wall Street Journal Online (Fri, Jan 15)
LaBranche, Rosetta Genomics: Early Volume Plays
at TheStreet.com (Thu, Jan 14)
Rosetta Genomics Ltd. to Raise $5.1 Million in Registered Direct Offering
Business Wire (Thu, Jan 14)
Rosetta Announces that Johns Hopkins University Researchers Demonstrate miRview squamous Classifies Non-Small Cell Lung Cancer with Extremely High Degree of Accuracy
Business Wire (Wed, Jan 13)
Rosetta Genomics Stockholders Elect Two New Directors at Annual Meeting
Business Wire (Wed, Dec 23)
ROSETTA GENOMICS LTD Earnings, Business Update & Pipeline Progress Call scheduled for 8:30 am ET today
CCBN (Sat, Dec 19)
Rosetta Genomics Reports Third Quarter Financial Results, Provides Business Update
Business Wire (Fri, Dec 18)
More Headlines for ROSG...

 ANALYST 
EPS Est (next year) () :N/A
EPS Est (in 2 years) () :N/A
Avg Rec (current)*:N/A
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices